drugset / Trial / NCT00637897
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase 1
Completed
24 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Paricalcitol may help chemotherapy drugs to kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This clinical trial is studying the best dose and best way to give paricalcitol and to see how well it works when given together with chemotherapy in treating patients with metastatic breast cancer.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-11
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paricalcitol | Other / unclassified | — | Oral |
| Background | Docetaxel | Small molecule | — | — |
| Background | Ixabepilone | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |